Comparing the fifteen most significantly enriched transcriptional regulators for each treatment, we found four that were shared between both treatments: AR, p53, glucocorticoid receptor (NR3C1) and MYC. Regulation of p53 [56] and NR3C1 [57] by AMPK has been previously demonstrated, confirming that our approach was able to identify established AMPK-regulated transcriptional pathways in prostate cancer cells. This evidence concerns the gene PRKAA1 and prostate cancer.